Corvus Pharmaceuticals, Inc. Aktie News

Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark.

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,185,101 additional shares, at a price to the public of $22...

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting disco...

Corvus Pharmaceuticals, Inc. reported highly positive phase 1 cohort 4 data for soquelitinib in moderate-to-severe atopic dermatitis. 75% of patients on 200 mg soquelitinib BID achieved EASI 75, with benefits persisting one month post-treatment. Longer treatment duration improved outcomes, including for patients previously treated with other therapies.

Corvus Pharmaceuticals, Inc. stock surged 165% on strong Phase 1 soquelitinib data in moderate-to-severe atopic dermatitis, including treatment-resistant patients. Soquelitinib achieved 75% EASI-75 and 33% IGA 0/1 rates, with favorable safety and biomarker evidence supporting its differentiated immunomodulatory mechanism. CRVS initiated a $150M equity offering to extend cash runway and fund piv...

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.